Showing 1731-1740 of 2150 results for "".
- Market Scope: China’s Ophthalmic Market to grow 11.3% to $4.5 Billion in 2023https://modernod.com/news/market-scope-chinas-ophthalmic-market-to-grow-11-3-to-4-5-billion-in-2023/2480211/Market Scope forecasts that China’s $2.6 billion ophthalmic market will grow at a compound annual rate of 11.3 percent over the next 5 years to $4.5 billion in 2023. China has tremendous unmet need for ophthalmic care. The country is home to approximately one-third of the world’s blind peo
- Aerie Pharmaceuticals Announces Appointment of Scott Laranjo as Director, Marketing, Roclatanhttps://modernod.com/news/aerie-pharmaceuticals-announces-appointment-of-scott-laranjo-as-director-marketing-roclatan/2480254/Aerie Pharmaceuticals announced the appointment of Scott Laranjo as Director, Marketing, Roclatan, reporting to Deanne Melloy, Aerie’s Vice President of Marketing. Mr. Laranjo will direct future marketing activities associated with Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005
- FDA Approves Marketing For First AI Device for Diabetic Retinopathy Detectionhttps://modernod.com/news/fda-permits-marketing-of-ai-based-device-to-detect-certain-diabetes-related-eye-problems/2480256/The FDA has permitted marketing for the first medical device to use artificial intelligence to detect greater than a mild level of diabetic retinopathy in adults who have diabetes. The device, called IDx-DR, is a software program that uses an artificial intelligence algorithm to analyze im
- Market Scope: Patient Demand for Better Vision Will Drive Double-Digit Growth in IOL Revenueshttps://modernod.com/news/patient-demand-for-better-vision-will-drive-double-digit-growth-in-iol-revenues/2480268/Technological innovations in premium IOLs will help drive global IOL revenues to more than $6.1 billion by 2023, according to Market Scope data.
- Heidelberg and NetraMind Collaborate to Deliver AI-Powered Choroid Analysis on AppWay Marketplacehttps://modernod.com/news/heidelberg-and-netramind-collaborate-to-deliver-ai-powered-choroid-analysis-on-appway-marketplace/2484166/Heidelberg Engineering announced a new collaboration with NetraMind Innovations, an AI-driven image analysis software company founded by retinal specialists and machine learning engineers. Their new application, NMI-ChoroidAI,* is now available via the Heidelb
- Brent Saunders: Bausch + Lomb to Return enVista IOLs to Market Following Voluntary Recallhttps://modernod.com/news/bausch-lomb-returning-envista-iols-to-market-following-voluntary-recall/2482752/Bausch + Lomb announced it has identified the event that led to its recent
- Biocon Biologics Secures Market Entry Date for Yesafili, Interchangeable Biosimilar to Eylea in the UShttps://modernod.com/news/biocon-biologics-secures-market-entry-date-for-yesafili-interchangeable-biosimilar-to-eylea-in-the-us/2482736/Biocon Biologics announced a settlement and license agreement with Regeneron that clears the way to commercialize Yesafili (aflibercept-jbvf), an interchangeable biosimilar aflibercept, in the United States. Yesafili, a vascular endothelial growth factor (VEGF) inhibitor, is used to tre
- Harrow Secures Medicare Part D Market Access for Vevyehttps://modernod.com/news/harrow-secures-medicare-part-d-market-access-for-vevye/2482535/Harrow announced that beginning January 1, 2025, Harrow’s dry eye disease treatment, Vevye, will be included in the formularies of major plan sponsors, including Express Scripts, Cigna, Kaiser Permanente, and CVS Caremark. Collectively, these plan sponsors provide coverage for more tha
- FDA Grants Notal Vision Home OCT System De Novo Marketing Authorizationhttps://modernod.com/news/fda-grants-notal-vision-home-oct-scanly-de-novo-marketing-authorization/2482282/Notal Vision announced that the FDA has granted De Novo authorization for its patient self-operated Scanly Home OCT device. Designated by the FDA as a breakthrough device for patients suffering from wet age-related macular degeneration (AMD), Scanly Home OCT aims to improve persona
- Harrow Partners with Healthcare Market Access Technology Platforms to Support Launch of Vevyehttps://modernod.com/news/harrow-partners-with-healthcare-market-access-technology-platforms-to-support-launch-of-vevye/2482037/Harrow announced that it has partnered with three healthcare technology platforms to expand US availability of dry eye drug Vevye (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, twice-daily (BID) ophthalmic solution based on a water-free semifluorinated alkane (